<SEC-DOCUMENT>0001193125-22-061399.txt : 20220301
<SEC-HEADER>0001193125-22-061399.hdr.sgml : 20220301
<ACCEPTANCE-DATETIME>20220301163604
ACCESSION NUMBER:		0001193125-22-061399
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220301
DATE AS OF CHANGE:		20220301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Social Capital Suvretta Holdings Corp. III
		CENTRAL INDEX KEY:			0001850270
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				981586514
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40560
		FILM NUMBER:		22698775

	BUSINESS ADDRESS:	
		STREET 1:		2850 W. HORIZON RIDGE PARKWAY
		STREET 2:		SUITE 200
		CITY:			HENDERSON
		STATE:			NV
		ZIP:			89052
		BUSINESS PHONE:		(650) 521-9007

	MAIL ADDRESS:	
		STREET 1:		2850 W. HORIZON RIDGE PARKWAY
		STREET 2:		SUITE 200
		CITY:			HENDERSON
		STATE:			NV
		ZIP:			89052
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d107023ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT PURSUANT TO SECTION 14(a) OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in Its Charter) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s)
Filing Proxy Statement, if other than the Registrant) </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11</FONT>
(set forth the amount on which the filing fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g107023dsp2.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ProKidney to Present REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> at 4<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Annual CKD Summit </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presentation to include data on Mechanism of Action, clinical trials
<FONT STYLE="white-space:nowrap">to-date</FONT> and current regulatory status</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Winston-Salem, NC,</B> March&nbsp;1, 2022 &#151;
ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease (ESRD) and need for dialysis,
today announced that Joseph Stavas, MD, MPH, Senior Vice President of Clinical Development, will present data on the Company&#146;s lead product candiate, Renal Autologous Cell Therapy
(REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) at the 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Annual CKD Summit, being held March <FONT STYLE="white-space:nowrap">1-3,</FONT> 2022 in Boston, MA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of Dr.&nbsp;Stavas&#146; presentation are as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation: </B>Renal autologous cell therapy (REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) to treat Type 2 Diabetic-related Chronic
Kidney Disease </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical trials with REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> have shown promising early
efficacy and safety results. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Individuals with Stage 3 and 4 type 2 diabetic CKD are target populations for restoration and stabilization of
renal function. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> has received Regenerative Medicine Advanced
Therapy (RMAT) designation, allowing the potential for expedited development. A global registrational clinical trial program for REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is currently underway. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date: </B>Thursday, March&nbsp;3, 2022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Time: </B>1:00
p.m. EST </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> has the potential to change the treatment paradigm for mid and late-stage
CKD patients with few other options than progression to ESRD. Unlike currently available approaches, which slow the progression of CKD, our novel cell therapy candidate aims to reverse the decline in renal function,&#148; said Dr.&nbsp;Stavas.
&#147;We recently reached an important milestone in the REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> program with the initiation of our first Phase 3 study, and look forward to sharing progress of our clinical programs with the
nephrology community at this important meeting.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the 4<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Annual CKD Summit </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leveraging advances in precision medicine, early biomarkers of efficacy, and evolving surrogate endpoints to take the next step in targeting CKD beyond SGLT2
inhibitors, the 4th Chronic Kidney Disease Drug Development Summit is dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into
rare renal disorders. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> has the potential to not only slow the progression of CKD, but in some cases drive meaningful
improvement in kidney function &#150; potentially a groundbreaking first in CKD therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A cell therapy product produced from a patient&#146;s own
kidney cells, REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> comprises a proprietary mixture of progenitor cells that have been grown and selected, so they can be placed back into the patient&#146;s kidney. This minimally invasive
procedure, starting with a standard biopsy, provides the cells that have the potential to harness the body&#146;s intrinsic ability to repair and restore damaged kidney tissue. The outpatient reinjection procedure has been well tolerated in clinical
trials to date, and if the required registrational trials are ultimately successful and REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is approved by regulatory authorities,
REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> could delay or prevent the need for conventional renal failure treatment options, such as dialysis and organ transplant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ProKidney </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ProKidney, a pioneer in the treatment of
chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney&#146;s lead product candidate, REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (Renal Autologous Cell
Therapy), is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-of-its-kind,</FONT></FONT></FONT> patented disease-modifying autologous cellular therapy with the potential to not only slow and
stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as
FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January&nbsp;18, 2022, ProKidney announced that it would become a publicly traded company via
a business combination with Social Capital Suvretta Holdings Corp. III (Nasdaq: DNAC). For more information, visit www.prokidney.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional
Information and Where to Find It </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed transaction between Social Capital Suvretta Holdings Corp.&nbsp;III (&#147;SCS&#148;)
and ProKidney LP (&#147;ProKidney&#148;), SCS filed a preliminary proxy statement with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) on February&nbsp;14, 2022 and intends to file a definitive proxy statement with the SEC.
SHAREHOLDERS OF SCS ARE ADVISED TO READ THE PRELIMINARY PROXY STATEMENT AND, WHEN AVAILABLE, ANY AMENDMENTS THERETO, THE DEFINITIVE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE
PROPOSED TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. HOWEVER, THESE DOCUMENTS WILL NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION. THEY ARE ALSO NOT INTENDED TO
FORM THE BASIS OF ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF THE PROPOSED TRANSACTION. When available, the definitive proxy statement will be mailed to the shareholders of SCS as of a record date to be established for voting on the
proposed transaction. Shareholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement and other documents filed with the SEC that will be incorporated by reference therein, without charge, once
available, at the SEC&#146;s website at http://www.sec.gov. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The documents filed by SCS with the SEC also may be obtained free of charge at SCS&#146;s website at
https://socialcapitalsuvrettaholdings.com/dnac or upon written request to 2850 W. Horizon Ridge Parkway, Suite 200, Henderson, NV 89052. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants
in the Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SCS and ProKidney and their respective directors and executive officers may be deemed to be participants in the solicitation of
proxies from SCS&#146;s shareholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction between ProKidney and SCS will be
contained in the definitive proxy statement when available. You may obtain free copies of these documents as described in the preceding paragraph. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No
Offer or Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in
respect of the proposed transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of
Section&nbsp;10 of the Securities Act of 1933, as amended or an exemption therefrom. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication may contain certain forward-looking statements within the meaning of the federal securities laws, including with respect to the proposed
transaction between ProKidney and SCS. These forward-looking statements generally are identified by the words &#147;believe,&#148; &#147;project,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;intend,&#148;
&#147;strategy,&#148; &#147;future,&#148; &#147;opportunity,&#148; &#147;plan,&#148; &#147;may,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would,&#148; &#147;will be,&#148; &#147;will continue,&#148; &#147;will likely result,&#148; and
similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i)&nbsp;the risk that the proposed transaction may not be completed in a timely manner or at all, which may
adversely affect the price of SCS&#146;s securities, (ii)&nbsp;the risk that the proposed transaction may not be completed by SCS&#146;s business combination deadline and the potential failure to obtain an extension of the business combination
deadline if sought by SCS, (iii)&nbsp;the failure to satisfy the conditions to the consummation of the proposed transaction, including the adoption of the definitive agreement related to the business combination between SCS and ProKidney (the
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;Business Combination Agreement&#148;) by the shareholders of SCS and the satisfaction of the minimum cash condition, (iv)&nbsp;the lack of a third party valuation in determining whether or
not to pursue the proposed transaction, (v)&nbsp;the inability to complete the private placement entered into in connection with the transaction, (vi)&nbsp;the occurrence of any event, change or other circumstance that could give rise to the
termination of the Business Combination Agreement, (vii)&nbsp;the effect of the announcement or pendency of the transaction on ProKidney&#146;s business relationships, operating results, and business generally, (viii)&nbsp;risks that the proposed
transaction disrupts current plans and operations of ProKidney and potential difficulties in ProKidney employee retention as a result of the transaction, (ix)&nbsp;the outcome of any legal proceedings that may be instituted against ProKidney or
against SCS related to the Business Combination Agreement or the proposed transaction, (x)&nbsp;the ability to maintain the listing of SCS&#146;s securities on a national securities exchange, (xi)&nbsp;the price of SCS&#146;s securities may be
volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which SCS plans to operate or ProKidney operates, variations in operating performance across competitors, changes in laws and regulations
affecting SCS&#146;s or ProKidney&#146;s business, and changes in the combined capital structure, (xii)&nbsp;the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify
and realize additional opportunities and (xiii)&nbsp;the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry. The foregoing list of factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described in the &#147;Risk Factors&#148; section of SCS&#146;s preliminary proxy statement on Schedule 14A (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40560)</FONT> filed with the SEC
on February&nbsp;14, 2022, SCS&#146;s quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2021 filed with the SEC on November&nbsp;15, 2021, the definitive proxy statement of SCS, when
available, including those under &#147;Risk Factors&#148; therein and other documents filed by SCS from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results
to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ProKidney and SCS
assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither ProKidney nor SCS gives any assurance that either ProKidney or SCS, or the
combined company, will achieve its expectations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lee Roth </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Burns McClellan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lroth@burnsmc.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) <FONT STYLE="white-space:nowrap">300-8331</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert Flamm, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Burns McClellan </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rlfamm@burnsmc.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g107023dsp2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g107023dsp2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M:QDE(E"@MU-83DYRNSJIP5.*BBS4F@4 % !0 4 % !0 4 % !0 4 % !0 4
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< * "@ H * "@ H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
